Three-quarters of persons in the US population reporting a clinical diagnosis of fibromyalgia do not satisfy fibromyalgia criteria: The 2012 National Health Interview Survey

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Walitt, Brian ^a   Katz, Robert S ^b   Bergman, Martin J ^c   Wolfe, Frederick ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FIBROMYALGIA; HEALTH CARE UTILIZATION; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; INSOMNIA; MALE; MUSCULOSKELETAL DISEASE ASSESSMENT; PAIN; POLYSYMPTOMATIC DISTRESS SCALE; PREVALENCE; UNITED STATES; WORK DISABILITY; FALSE POSITIVE RESULT; PREGNANCY;

ADULT; FALSE POSITIVE REACTIONS; FEMALE; FIBROMYALGIA; HUMANS; MALE; PREGNANCY; UNITED STATES;

EID: 84975487859     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157235     Document Type: Article

References (33)

1. Walitt B, Nahin RL, Katz RS, Bergman MJ, Wolfe F. The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey. PLoS One. 2015; 10(9):e0138024. doi: 10.1371/journal.pone.0138024 PMID: 26379048.
2. Walitt B, Nahin, R., Katz R., Bergman M., Wolfe F. The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey. 2015.
3. Skaer TL. Fibromyalgia: disease synopsis, medication cost effectiveness and economic burden. PharmacoEconomics. 2014; 32(5):457-66. doi: 10.1007/s40273-014-0137-y PMID: 24504852.
4. Smythe HA, Moldofsky H. Two contributions to understanding of the "fibrositis" syndrome. Bulletin on the rheumatic diseases. 1977; 28(1):928-31. PMID: 199304.
5. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and rheumatism. 1990; 33(2):160-72. PMID: 2306288.
6. Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. The Journal of rheumatology. 2009; 36(10):2318-29. doi: 10.3899/jrheum.090367 PMID: 19820221; PubMed Central PMCID: PMC3419373.
7. Wolfe F. The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis. 1997; 56(4):268-71. PMID: 9166001; PubMed Central PMCID: PMC1752352.
8. Petzke F, Gracely RH, Park KM, Ambrose K, Clauw DJ. What do tender points measure? Influence of distress on 4 measures of tenderness. The Journal of rheumatology. 2003; 30(3):567-74. PMID: 12610818.
9. Wolfe F, Clauw D, Fitzcharles MA, Goldenberg D, Katz RS, Mease P, et al. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care Res. 2010; 62(5):600-10.
10. Wolfe F, Clauw D, Fitzcharles MA, Goldenberg D, Häuser W, Katz RS, et al. Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011; 38:1113-22. doi: 10.3899/jrheum.100594 PMID: 21285161
11. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC musculoskeletal disorders. 2007; 8:27. doi: 10.1186/1471-2474-8-27 PMID: 17349056; PubMed Central PMCID: PMC1829161.
12. Hauser W, Urrutia G, Tort S, Uceyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. The Cochrane database of systematic reviews. 2013; 1: CD010292. doi: 10.1002/14651858.CD010292 PMID: 23440848.
13. Uceyler N, Sommer C, Walitt B, Hauser W. Anticonvulsants for fibromyalgia. The Cochrane database of systematic reviews. 2013; 10:CD010782. doi: 10.1002/14651858.CD010782 PMID: 24129853.
14. Robinson RL, Kroenke K, Williams DA, Mease P, Chen Y, Faries D, et al. Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the reflections study. Pain medicine. 2013; 14(9):1400-15. doi: 10.1111/pme.12168 PMID: 23758985.
15. Wolfe F, Hassett AL, Walitt B, Michaud K. Mortality in fibromyalgia: a study of 8,186 patients over thirtyfive years. Arthritis Care Res (Hoboken). 2011; 63(1):94-101. doi: 10.1002/acr.20301 PMID: 20662040.
16. Gupta A, Silman AJ, Ray D, Morriss R, Dickens C, MacFarlane GJ, et al. The role of psychosocial factors in predicting the onset of chronic widespread pain: results from a prospective population-based study. Rheumatology (Oxford). 2007; 46(4):666-71. Epub 2006/11/07. kel363 [pii] doi: 10.1093/rheumatology/kel363 PMID: 17085772.
17. Nakamura I, Nishioka K, Usui C, Osada K, Ichibayashi H, Ishida M, et al. An epidemiologic internet survey of fibromyalgia and chronic pain in Japan. Arthritis Care Res (Hoboken). 2014; 66(7):1093-101. doi: 10.1002/acr.22277 PMID: 24403219.
18. Wolfe F, Brahler E, Hinz A, Hauser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res (Hoboken). 2013; 65(5):777-85. doi: 10.1002/acr.21931 PMID: 23424058.
19. National Center for Health Statistics. Data File Documentation, National Health Interview Survey, 2012 (machine readable data file and documentation). In: Statistics NCfH, editor. Hyattsville, Maryland: Centers for Disease Control and Prevention,; 2013. p. 1-135.
20. Walitt B, Nahin RL, Katz RS, Bergman M, Wolfe F. The Prevalence and Characteristics of Fibromyalgia in the 2012 National Health Interview Survey. PloS One. 2015.
21. Corporation S. Stata Statistical Software: Release 13.1. College Station, TX: Stata Corporation; 2013.
22. Wolfe F, Walitt BT, Rasker JJ, Katz RS, Hauser W. The Use of Polysymptomatic Distress Categories in the Evaluation of Fibromyalgia (FM) and FM Severity. The Journal of rheumatology. 2015. doi: 10.3899/jrheum.141519 PMID: 26077414.
23. Wolinsky H. Disease mongering and drug marketing. EMBO reports. 2005; 6(7):612-4. PMID: 15995678
24. Garfield SR. The delivery of medical care. Scientific American. 1970; 222(4):15-23. PMID: 5417825.
25. Association AP. Diagnostic and statistical manual of mental disorders: DSM-5. Amer Psychiatric Pub Inc; 2013. p. 991.
26. Hauser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis research & therapy. 2014; 16(1):201. doi: 10.1186/ar4441 PMID: 24433463; PubMed Central PMCID: PMC3979124.
27. Walitt B, Urrutia G, Nishishinya MB, Cantrell SE, Hauser W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. The Cochrane database of systematic reviews. 2015; 6:CD011735. doi: 10.1002/14651858.CD011735 PMID: 26046493; PubMed Central PMCID: PMC4755337.
28. Walitt B, Fitzcharles MA, Hassett AL, Katz RS, Hauser W, Wolfe F. The longitudinal outcome of fibromyalgia: a study of 1555 patients. The Journal of rheumatology. 2011; 38(10):2238-46. doi: 10.3899/jrheum.110026 PMID: 21765102.
29. Szabo RM, King KJ. Repetitive stress injury: diagnosis or self-fulfilling prophecy? The Journal of bone and joint surgery American volume. 2000; 82(9):1314-22. PMID: 11005523.
30. CDC. Vital Signs: Prescription Painkiller Overdoses. 2013.
31. Conrad P, Mackie T, Mehrotra A. Estimating the costs of medicalization. Soc Sci Med. 2010; 70(12):1943-7. doi: 10.1016/j.socscimed.2010.02.019 PMID: 20362382.
32. Conrad P. The shifting engines of medicalization. Journal of health and social behavior. 2005; 46(1):3-14. PMID: 15869117.
33. Furedi F. The End of Professional Dominance. Society. 2006; 43(6):14-8.